Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks - PubMed
3 days ago
- #Alzheimer's disease
- #Biomarkers
- #Plasma p-tau217
- Plasma p-tau217 clocks can predict the onset of symptomatic Alzheimer's disease (AD).
- The study used longitudinal plasma %p-tau217 data from two cohorts (n=258 and n=345) to estimate the age at plasma %p-tau217 positivity.
- The estimated age at plasma %p-tau217 positivity correlated with the age at onset of AD symptoms (adjusted R² of 0.337-0.612), with a median absolute error of 3.0-3.7 years.
- Older individuals showed a shorter time from %p-tau217 positivity to the onset of AD symptoms.
- Similar predictive models were constructed using data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays.
- The findings suggest that a single blood test can estimate the time until AD symptom onset within an acceptable margin of error for clinical trials.
- The study involved multiple researchers with various conflicts of interest, including consulting roles and patents related to AD biomarkers and therapeutics.
- Funding was provided by the U.S. National Institute on Aging and other sources.